Aurobindo Pharma Limited (BOM:524804)

Market Cap	665.37B -2.6%
Revenue (ttm)	331.82B +7.3%
Net Income	34.87B -0.1%
EPS	60.04 +0.4%
Shares Out	n/a
PE Ratio	19.08
Forward PE	16.11
Dividend	4.00 (0.35%)
Ex-Dividend Date	Aug 8, 2025

Volume	16,694
Average Volume	87,543
Open	1,154.85
Previous Close	1,157.55
Day's Range	1,127.30 - 1,157.10
52-Week Range	994.35 - 1,278.00
Beta	n/a
RSI	45.66
Earnings Date	Feb 9, 2026

About Aurobindo Pharma

Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretrovira...

• Industry: Pharmaceutical Preparations
• Founded: 1986
• Employees: 27,707
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524804

Financial Performance

In fiscal year 2025, Aurobindo Pharma's revenue was 317.24 billion, an increase of 9.39% compared to the previous year's 290.02 billion. Earnings were 34.86 billion, an increase of 9.86%.